- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Post Abdominal Surgery Pain
- Interventions
- CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more
- Conditions
- Osteoarthritis
- Interventions
- CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
- Interventions
- CR845 tablet 1 mg, CR845 tablet 2.5 mg, CR845 tablet 5 mg, Placebo tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 761 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Acute Pain
- Interventions
- CR845, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 60 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 12
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 83
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more